SBIR Phase I: Development of a Novel, Cost-Effective Gait Training Device Utilized at Home for the Neurological Patient Population

这个小企业创新（SBIR）第一阶段项目的更广泛的影响/商业潜力将是开发一种神经康复技术，其潜在市场总额为美元。54 B和机会，以增加获得先进的护理，为520万人在美国生活与瘫痪和130万人，每年经历一个极端的神经损伤或诊断，可导致严重的步态障碍这项技术将鼓励积极主动的护理方法，消除临床医生在康复体验中的身体存在的需要，并引入软件解决方案来增加动力和连通性。临床上，如果成功，这项技术可以大大减少继发性并发症，帮助人们恢复行走能力，并最终降低与神经诊断相关的成本。这项小型企业创新研究（SBIR）第一阶段是开发一种家用步态训练器，用于神经损伤或神经疾病患者的康复和物理治疗，采用以患者为中心的方法。该项目将先进的家庭医疗技术与远程医疗物理治疗相结合。 该奖项反映了NSF的法定使命，并通过使用基金会的智力价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation (SBIR) Phase I project would be the development of a neurorehabilitation technology with a total addressable market of $54B and the opportunity to increase access to advanced care for the 5.2 million people in the US living with paralysis and the 1.3 million people each year that experience an extreme neurological injury or diagnosis that can lead to severe gait impairment. This technology will encourage a proactive approach to care, eliminate the need for a clinician to be physically present in the rehabilitation experience, and introduce software solutions to increase motivation and connectivity. Clinically, if successful, this technology could dramatically decrease secondary complications, help people regain the ability to walk, and ultimately reduce costs associated with neurological diagnoses.This Small Business Innovation Research (SBIR) Phase I is to develop an at-home gait trainer for rehabilitation and physical therapy of individuals with neurological injuries or neurological conditions using a patient-centered approach. This project integrates at-home advanced medical technology with telemedicine physical therapy. This will enable continued rehabilitation and physical therapy without clinical oversight via training videos.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.